The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 28, Issue 4, 2011, Pages 395-413

  Janssen, M F ^a   Lubetkin, E I ^a,b   Sekhobo, J P ^c   Pickard, A S ^a,d  

^a EuroQol Group Executive Office   (Netherlands)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^c NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Diabetes; Modelling; Psychometrics; Quality of life

Indexed keywords

HEMOGLOBIN A1C;

AGE; AMPUTATION; BLINDNESS; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISCRIMINANT VALIDITY; DISEASE DURATION; DISEASE SEVERITY; EQ 5D PREFERENCE BASED HEALTH STATUS MEASURE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEG DISEASE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; POLYNEUROPATHY; PROTEINURIA; QUALITY OF LIFE; REVIEW; STROKE; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VERTEBRA MALFORMATION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; REPRODUCIBILITY OF RESULTS;

EID: 79952497188     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03136.x     Document Type: Review

References (93)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. World Health Organization. Diabetes: Key Facts. Available at: Last accessed 6 June 2009.
3. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008; 31: 596-615.
4. Diabetes UK. Diabetes. Beware the Silent Assessin. A report from Diabetes UK, October 2008. Available at: Last accessed 23 December 2009.
5. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. J Am Med Assoc 2003; 290: 1884-1890.
6. Maddigan SL, Majumdar SR, Toth EL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with varying degrees of disease severity in type2 diabetes. Health Qual Life Outcomes 2003; 1: 78.
7. Kind P. Introduction to diabetes special issue of value in health. Value Health 2000; 3: S1-2.
8. Luscombe FA. Health-related quality of life measurement in type2 diabetes. Value Health 2000; 3: S15-28.
9. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes. Diabet Med 2009; 26: 315-327.
10. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005; 14: 1311-1320.
11. Campbell IW. Epidemiology and clinical presentation of type2 diabetes. Value Health 2000; 3: S3-6.
12. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 2006; 9: 213-218.
13. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-343.
14. Lubetkin EI, Gold MR. Areas of decrement in health-related quality of life (HRQL): comparing the SF-12, EQ-5D, and HUI 3. Qual Life Res 2003; 12: 1059-1067.
15. Macran S, Weatherly H, Kind P. Measuring population health - a comparison of three generic health status measures. Med Care 2003; 41: 218-231.
16. Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA et al. Validity and responsiveness of the Euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res 2002; 11: 273-282.
17. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8: 9-16.
18. Willige Gvd, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005; 14: 441-451.
19. EuroQol Group. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Dordrecht: Springer, 2007.
20. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637.
21. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
22. Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001; 21: 288-294.
23. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005; 43: 736-749.
24. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-3317.
25. Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007; 25: 365-384.
26. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008; 35: 592-602.
27. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-1900.
28. Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med 2008; 102: 519-536.
29. Zaza S, Wright-De Aguero LK, Briss PA, Truman BI, Hopkins DP, Hennessy MH et al. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services, Task Force on Community Preventive Services. Am J Prev Med 2000; 18: 44-74.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
31. Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med 2007; 8: 410-418.
32. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005; 14: 217-230.
33. Barton GR, Sach TH, Doherty M, Avery AJ, Jenkinson C, Muir KR. An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ 2008; 9: 237-249.
34. Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 2003; 12: 413-425.
35. Bharmal M, Thomas J III. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006; 9: 262-271.
36. Bowman L, Juarez RKL, Secnik BK, Shi L, Coons SJ. Comparison of US and UK population preference based EQ-5D index scores across four disease states: baseline-to-endpoint change scores. In: Badia X, ed. Proceedings of the 23rd EuroQol Plenary Meeting, Barcelona, Spain, 14th-16th September, 2006: 437-456.
37. Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001; 55: 51-69.
38. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621-635.
39. Cavrini G, Pacelli B, Pandolfi P, Collina N, Mezzetti F, Pesci P et al. Modelling EQ-5D dimensions for the purpose of identifying perceived health impact of lifestyle determinants. In: Pickard AS, ed. Proceedings of the 21st EuroQol Plenary Meeting, Chicago, USA, 16th-18th September, 2004: 29-44.
40. Chancellor J, Aballea S, Lawrence A, Sheldon R, Cure S, Plun-Favreau J et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008; 26: 217-234.
41. Clarke P, Gray A, Holman R. Estimating utility values for health states of type2 diabetic patients using the EQ-5D (UKPDS62). Med Decis Making 2002; 22: 340-349.
42. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20000 subjects. Value Health 2005; 8: 581-590.
43. Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD et al. The financial costs of healthcare treatment for people with Type1 or Type2 diabetes in the UK, with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007; 24: 187-194.
44. Department of Health. Health Survey for England 1996. London: Department of Health, 1997.
45. Dunning J, Waller JR, Smith B, Pitts S, Kendall SW, Khan K. Coronary artery bypass grafting is associated with excellent long-term survival and quality of life: a prospective cohort study. Ann Thorac Surg 2008; 85: 1988-1993.
46. Glasziou P, Alexander J, Beller E, Clarke P. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type2 diabetes in the ADVANCE trial Health Qual Life Outcomes 2007; 5: 21.
47. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374-385.
48. Gorter K, van BR, Stolk R, Zuithoff P, Verhoeven R, Rutten G. Overall quality of diabetes care in a defined geographic region: different sides of the same story. Br J Gen Pract 2008; 58: 339-345.
49. Grandy S, Fox KM. EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Health Qual Life Outcomes 2008; 6: 18.
50. Hayes AJ, Clarke PM, Glasziou PG, Simes RJ, Drury PL, Keech AC. Can self-rated health scores be used for risk prediction in patients with type2 diabetes? Diabetes Care 2008; 31: 795-797.
51. Hervas A, Zabaleta A, De MG, Beldarrain O, Diez J. Calidad de vida relacionada con la salud en pacientes con diabetes mellitus tipo 2. (Health related quality of life in patients with diabetes mellitus type 2.). An Sist Sanit Navar 2007; 30: 45-52.
52. Hoffman DL, Sadosky A, Alvir J. Cross-national burden of painful diabetic peripheral neuropathy in Asia, Latin America, and the Middle East. Pain Pract 2009; 9: 35-42.
53. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality of life in type2 diabetes (TARDIS-2). Value Health 2000; 3: S47-51.
54. INDINEP. Burden of neuropathic pain in Indian patients attending urban, specialty clinics: results from a cross sectional study. Pain Pract 2008; 8: 362-378.
55. Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998; 7: 155-166.
56. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000; 38: 115-121.
57. Johnson JA, Pickard AS, Conner-Spady B Longitudinal changes in health-related quality of life of people with diabetes compared to those without chronic conditions. In: Badia X, ed. Proceedings of the 17th EuroQol Plenary Meeting, Pamplona, Spain, 28th-29th September, 2010: 193-206.
58. Kelley K, Dempsey C. An evaluation of an insulin transfer programme delivered in a group setting. J Clin Nurs 2007; 16: 152-158.
59. Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res 2009; 18: 87-97.
60. Koopmanschap M. Coping with TypeII diabetes: the patient's perspective. Diabetologia 2002; 45: S18-S22.
61. Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005; 22: 1482-1486.
62. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med 2008; 25: 618-624.
63. Lubetkin EI, Jia H, Franks P, Gold MR. Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the US general population. Qual Life Res 2005; 14: 2187-2196.
64. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. The costs of type2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2: 121-133.
65. Luo N, Johnson JA, Shaw JW, Coons SJ. Relative efficiency of the EQ-5D, HUI2, and HUI3 in a US population survey. In: Pickard AS, ed. Proceedings of the 21st EuroQol Plenary Meeting, Chicago, USA, 16th-18th September, 2004: 121-134.
66. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health related quality of life in hemodialysis patients. ASAIO J 2002; 48: 565-569.
67. Mata CM, Roset GM, Badia X, Antonanzas VF, Ragel AJ. Impacto de la diabetes mellitus en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. (Effect of type2 diabetes mellitus on the quality of life of patients treated at primary care consultations in Spain.). Aten Primaria 2003; 31: 493-499.
68. Matza LS, Boye KS, Yurgin N. Validation of two generic patient-reported outcome measures in patients with type2 diabetes. Health Qual Life Outcomes 2007; 5: 47.
69. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM et al. Utilities and disutilities for type2 diabetes treatment-related attributes. Qual Life Res 2007; 16: 1251-1265.
70. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med 2006; 23: 1100-1105.
71. Ragnarson TG, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications 2000; 14: 235-241.
72. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9: 29-40.
73. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type2 diabetes. Diabetes Care 2002; 25: 458-463.
74. Saarni SI, Harkanen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006; 15: 1403-1414.
75. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H et al. Measurement of HRQL using EQ-5D in patients with type2 diabetes mellitus in Japan. Value Health 2006; 9: 47-53.
76. Sakthong P, Charoenvisuthiwongs R, Shabunthom R. A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type2 diabetes. Health Qual Life Outcomes 2008; 6: 71.
77. Secnik BK, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type2 diabetes. Health Qual Life Outcomes 2006; 4: 80.
78. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A. Cost-effectiveness of self monitoring of blood glucose in patients with non-insulin treated type2 diabetes: economic evaluation of data from the DiGEM trial. Br Med J 2008; 336: 1177-1180.
79. Smith DH, Johnson ES, Russell A, Hazlehurst B, Muraki C, Nichols GA et al. Lower visual acuity predicts worse utility values among patients with type2 diabetes. Qual Life Res 2008; 17: 1277-1284.
80. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005; 43: 736-749.
81. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006; 20: 26-33.
82. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008; 12: 203-213.
83. UKPD Study Group. Quality of life in type2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS37). UK Prospective Diabetes Study Group. Diabetes Care 1999; 22: 1125-1136.
84. van Schoor NM, Smit JH, Twisk JW, Lips P. Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int 2005; 16: 749-756.
85. Vernon MK, Brandenburg NA, Alvir JM, Griesing T, Revicki DA. Reliability, validity, and responsiveness of the daily sleep interference scale among diabetic peripheral neuropathy and postherpetic neuralgia patients. J Pain Symptom Manage 2008; 36: 54-68.
86. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008; 10: S16-24.
87. Wang HM, Beyer M, Gensichen J, Gerlach FM. Health-related quality of life among general practice patients with differing chronic diseases in Germany: cross-sectional survey. BMC Public Health 2008; 8: 246.
88. Wee HL, Tan CE, Goh SY, Li SC. Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) questionnaire in patients with diabetes in a multi-ethnic Asian country. Pharmacoeconomics 2006; 24: 673-682.
89. Wrobel MP, Szymborska-Kajanek A, Wystrychowski G, Biniszkiewicz T, Sieron-Stoltny K, Sieron A et al. Impact of low frequency pulsed magnetic fields on pain intensity, quality of life and sleep disturbances in patients with painful diabetic polyneuropathy. Diabetes Metab 2008; 34: 349-354.
90. Houle C, Bertheloth CM, Health Analysis and Modeling Group. Head-to-head comparison of the Health Utilities Index Mark 3 and the EQ-5D for the population living in private households in Canada. Qual Life Newsletter 2000; 24: 5-6.
91. Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998; 7: 311-322.
92. Kaarlola A, Pettila V, Kekki P. Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Med 2004; 30: 2245-2252.
93. EuroQol Group. Development and Preliminary Testing of an Official Five-Level Version of EQ-5D. Available at: Last accessed 21 November 2009.